Labcorp Secures FDA Approval for Advanced Melanoma Diagnostic Kit

Key Facts

In a move that advances precision medicine in the diagnostic sector, Labcorp has received FDA approval for its PGDx elio tissue complete CDx genomic test. This diagnostic kit will serve as a companion tool for advanced melanoma patients, utilizing next-generation sequencing to identify BRAF variants in stage IV cases. The approval is designed to help clinicians determine patient eligibility for specific targeted therapies, thereby streamlining critical treatment decisions.

This regulatory milestone provides a kit-based solution that hospitals can implement directly, which is vital given the low five-year survival rates associated with advanced melanoma. According to reports, decentralized testing allows for faster turnaround times compared to centralized laboratory models. This development is viewed as a positive expansion of Labcorp's oncology diagnostic portfolio, strengthening its position within the broader healthcare market.

Regarding market performance, LH stock stood at $319.17 (at close August 07, 2026), having reached a session high of $319.94. Investors are monitoring broader economic indicators, such as the U.S. Balance of Trade data, following the release of JOLTs Job Openings which came in at 7.359 million on August 04, 2026, as these factors continue to influence sentiment across the healthcare and diagnostics sectors.